Crown Bioscience, Inc. has acquired Molecular Response’s PDX models and PDX service operations, expanding its translational oncology services.
Crown gains Molecular Response’s existing PDX models as well as 8,000 viable human tumors for model development, with the ability to further select and develop models from a wider collection. The majority of these tissues come from patients who have received prior treatment, many from metastatic tumors. Each tumor is supported by a companion molecular biobank and a suite of patient and sample data representing more than 76 clinical diagnoses.
Molecular Response’s facilities and personnel in San Diego will be designated as a global center of excellence for Translational Oncology, expanding Crown’s existing operations in Beijing, Shanghai, Kannapolis, North Carolina and the UK.
“This acquisition represents the next step in Crown’s strategy to be the dominant provider of translational oncology drug discovery services”, comments Jean-Pierre Wery, president of Crown Bioscience. “Crown’s unique, clinically relevant models reflect the patient situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumors and metastasis, as well as being ethnically diverse and representing both treated and drug naïve patients. Our clients are now in a position to access a unique resource of relevant models containing clinically proven molecular markers present in global populations.”
